8,10-diaza-bicyclo[4.3.1]decane derivatives and their medical use
This invention relates to novel 8,10-diaza-bicyclo[4.3.1]decane derivatives, which are found to be cholinergic ligands at the nicotinic acetylcholine receptors. Due to their pharmacological profile the compounds of the invention may be useful for the treatment of diseases or disorders as diverse as those related to the cholinergic system of the central nervous system (CNS), the peripheral nervous system (PNS), diseases or disorders related to smooth muscle contraction, endocrine diseases or disorders, diseases or disorders related to neuro-degeneration, diseases or disorders related to inflammation, pain, and withdrawal symptoms caused by the termination of abuse of chemical substances.
1. A compound represented by Formula I
or a pharmaceutically acceptable salt thereof, wherein
A represents a pyridazinyl group;
L represents a single bond or a linking group —C≡C—;
B represents a phenyl or thienyl group, optionally substituted one or two times with substituents selected from alkyl, cycloalkyl, hydroxyl, alkoxy, halo and trifluoromethyl; and
R represents hydrogen or alkyl.
2. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein
L represents a single bond.
3. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein B represents a phenyl or thienyl group.
4. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein R represents hydrogen or alkyl.
5. The compound of claim 1 , which is
10-Methyl-8-(6-phenyl-pyridazin-3-yl)-8,10-diaza-bicyclo[4.3.1]decane;
10-Methyl-8-(6-phenylethynyl-pyridazin-3 -yl)-8,10-diaza -bicyclo [4.3.1]decane;
10-Methyl-8-(6-thiophen-3-yl-pyridazin-3-yl)-8,10-diaza -bicyclo [4.3.1]decane; or
10-Methyl-8-(6-thiophen-2-yl-pyridazin-3-yl)-8,10-diaza -bicyclo [4.3.1]decane;
or a pharmaceutically acceptable salt thereof.
6. A pharmaceutical composition comprising a therapeutically effective amount of the compound of claim 1 , or a pharmaceutically acceptable addition salt thereof, together with at least one pharmaceutically acceptable carrier or diluent.
7. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein L represents a linking group —C≡C—.
8. The compound of claim 1 , wherein B represents phenyl.
9. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein R represents alkyl.
10. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein R represents methyl.